All Type of News
KFDA to set fast review standards for new BT products.
To expedite rapid commercialization of the bio drugs, the health regulatory agency is going to establish a review standard and a supporting system, which may guide for the BT R&D to see its direction far in advance or...
Hanmi to reinforce injectable anticancer drug lines.
Hanmi announced recently to launch 2 injectable anti-cancer drugs such as Gembin (Gemcitabine) for the indication of non-small cell lung, bladder and pancreatic cancers and Inotecan (Irinotecan) in April and Liplatin ...
MOHW and AZ to agree more R&D cooperation.
The MOHW has made an MOU with AstraZeneca (AZ), a British based foreign multinational drug corporation, for the R&D and clinical study cooperation at a global level.
Minister Ryu Si-min signed the MOU on April 5 ...
2005 business performances varied in foreign drug corporations.
The business performance in 2005 by most of foreign multinational drug corporations showed that some company made remarkable sales while net incomes substantially setback.
Pfizer Korea having kept the top ran...
30 drug makers to commit no use of sodium benzoate.
30 beverage companies decided to strengthen their self QC in controlling the use of sodium benzoate as a preservative so that it may not be detected from their drink preparations.
The Korea Food Industry Associatio...
Two drug wholesalers reported 2005 business performances.
Union reported 93,800 MW of sales in 2005, 22.57% up from the previous year, 1,250 MW of operating income (65.05% up), 1,053 MW of ordinary income (400 MW more than the previous year) and 770 MW of net income, 44.88% ...
R&D infra for New drugs to be driven by KFDA.
Under the KFDA's leadership, it is expected that "2007 New Drug Infra Buildup Project" seems to run for the activation of the new drug development as a pan national strategic projects.
The lst 5 year plan starts fr...
SPA on long term battle against Novo Nordisk
The Seoul Pharmaceutical Association (chairman: Kwon Tae-jeong) may continue the protesting rally against Novo Nordisk without time limits.
The SPA took the second rally against Novo Nordisk who rejected the retur...
Schering Korea sold 89.8 BW of sales in 2005.
Schering Korea reported the 2005 business performance at 89,885 MW of sales (8.7% up from the previous year), 6,693 MW of operating income (18.5% up), 5,600 MW of ordinary income (a rise compared to 3,374 MW in 2004) ...
A large scale of logistic center to build by Samwon.
A typical and long running Busan drug wholesaler, Samwon (chairman: Choo Ki-yeop) announced on April 5 that the company planned to construct a large scale of logistic center at Suyoung district, Busan city having more...
